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Abstract
MicroRNA (miRNA) plays a critical role in a wide variety of biological processes. Profiling miRNA expression during
differentiation of embryonic stem cells will help to understand the regulation pathway of differentiation, which in turn may
elucidate disease mechanisms. The identified miRNAs could then serve as a new group of possible therapeutic targets. In the
present paper, miRNA expression profiles were determined during cardiomyocyte-specific differentiation and maturation of
murine embryonic stem (ES) cells. For this purpose a homogeneous cardiomyocyte population was generated from a
transgenic murine ES cell line. Two high throughput array platforms (Affymetrix and Febit) were used for miRNA profiling in
order to compare the effect of the platforms on miRNA profiling as well as to increase the validity of target miRNA
identification. Four time points (i.e. day 0, day 12, day 19 and day 26) were chosen for the miRNA profiling study, which
corresponded to different stages during cardiomyocyte-specific differentiation and maturation. Fifty platform and pre-
processing method-independent miRNAs were identified as being regulated during the differentiation and maturation
processes.Theidentification of thesemiRNAs is an important step for characterizing and understanding the eventsinvolved in
cardiomyocyte-specific differentiation of ES cells and may also highlight candidate target molecules for therapeutic purposes.
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Introduction
Embryonic stem cells (ES cells) are pluripotent cell lines
generated from the inner cell mass of blastocysts [1]. The
spectrum applications of ES cells is diverse and includes drug
discovery, high-throughput toxicology assays, regenerative medi-
cine and embryology [2,3]. Primary cells, such as hepatocytes or
cardiomyocytes cannot be maintained in culture for long periods
of time [4,5,6]. Furthermore, there is a strong donor-dependent
variability [7]. This is not a problem for immortalized cell lines,
however, they have been shown to be genetically unstable and do
not fully emulate the features of their primary cell counterparts. In
contrast, ES cells have an almost unlimited self-renewal capacity in
their undifferentiated state and the ability to differentiate into fully
mature cells of all cell types of the three embryonic germ layers
[8,9]. Thus, ES cells may constitute a unique source of
differentiated cell types and, as such, the regulation of their
differentiation pathways is under intensive study.
The phenotype of a cell is controlled by gene regulation, which is
the basis for cell differentiation, morphogenesis and the adaptability
of cells [10,11]. Modification of gene expression can occur at
different levels. Apart from epigenetic mechanisms (cytosine
methylation, histone acetylation), regulation can be observed at
the level of transcription initiation (transcription factors), hetero-
nucleic transcript processing (RNA splicing), mRNA transport from
the nucleus into the cytoplasm (nucleocytoplasmatic transport
factors, e.g. exportin-5), translation and post-translational modifi-
cations [12,13]. It has recently become evident that the previously
widely ignored non-protein coding genes play an important role in
the control of gene expression. MicroRNAs (miRNA) have become
one of the most important regulation factors and an understanding
of their expression and influence during ES cell differentiation will
help in the elucidation of the whole process [14,15]. In contrast to
single analysis, miRNA expression can be profiled in a more time-
and cost-effective manner by applying microarray technology [16].
Results from different microarray platforms are not always very well
correlated even for same samples due to differences in design,
manufacturing, hybridization condition, and label/detection meth-
ods. In practice, microarray data are often verified using other
techniques, such as RT-qPCR, but in principle, the result from one
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25809high throughput platform could also be verified with another
independent high throughput platform.
Inthe presentstudy, both AffymetrixmiRNA 1.0arraysand Febit
Biochips miRNA arrays were used in profiling miRNA expression
during controlled differentiation of mouse ES cells to cardiomyo-
cytes. Affymetrix miRNA 1.0 arrays cover 610 mouse miRNAs and
Febit miRNA arrays cover 719 miRNAs, 609 of which are common
to both platforms. Febitarraysprovide additionalinformation of 110
miRNA for mouse, while Affymetrix arrays have one miRNA
(miR699) that is not covered by the Febit array.
Affymetrix applies photolithography in-situ oligo synthesis
technology, which enables very high feature numbers on chips
[17]. Oligonucleotides with a maximum length of 25mer were
synthesized directly on chip. The GeneChipH miRNA Array
covers miRNAs from 71 organisms on a single array including
human, mouse and rat. The GeneChip miRNA Array also
includes human small nucleolar RNAs (snoRNAs and scaRNAs),
which are short, non-translated RNAs that play a role in the
processing of ribosomal RNAs following transcription. snoRNAs
have also been implicated in the regulation of alternative splicing.
Samples were labeled with biotin before hybridization and stained
with fluorescent labeled streptavidin after hybridization.
In contrast to Affymetrix technology, Febit Biochips were
produced using light-activated in-situ oligonucleotide synthesis by
means of a digital micromirror device. The probes aredesigned as the
reverse complements of all major mature miRNAs and the mature
sequences as published in the Sanger miRBase release (version 14.0
September 2009, see http://microrna.sanger.ac.uk/sequences/in-
dex.shtml) for mus musculus. Additional nucleotides are bound on
the 59-end of each capture oligonucleotide necessary for the on-chip
labeling technology MPEA (Microfluidic Primer Extension Assay).
This special procedure extends and labels perfectly hybridized probes
directlyon the chip. With this method,noise resulting from mismatch
probes is expected to be reduced.
Due to the great differences in probe design, array production
and hybridization techniques used to generate Affymetrix- and
Febit-miRNA arrays, they can both be considered as two entirely
independent platforms.
To investigate the processes of cardiac differentiation of mouse ES
cells, we are interested in miRNA profiling during cardiomyocyte-
specific differentiation and maturation events. To date, considerable
effort has been made in the establishment of reproducible protocols to
control stem cell growth and differentiation. Regardless of the large
variety of differentiation protocols that have been established, it is
difficult to generate a uniform population of cells [18,19]. In order to
collect valid results to understand a specific differentiation process it is
particularly important to have homogeneous, synchronized and clonal
cell populations available for the undifferentiated as well as for the
differentiated cell type. For this reason, a transgenic mouse ES cell
clone was used in our experiments. This clone is derived from D3 ES
cells [20] that had been stably transfected with DNA constructs
allowing the expression of puromycin resistance (PAC) gene and
enhanced green fluorescent protein (EGFP) reporter gene under the
control of mouse cardiac-specific a ˜-myosin heavy chain (a ˜-MHC)
promoter. Through induced differentiation and selection a highly
pure cardiomyocyte cell population (.99.9%) can be produced. Such
Cor.AtH cardiomyocytes are fully functional cardiomyocytes which
contract spontaneously and rhythmically and express cardiac-specific
genes including those relevant for cardiocyte ion channels [21,22].
When transplanted into a cryoinfarcted area of the mouse heart, such
donor cells fully integrate into the host cardiac tissue and restore
functionality [22]. With the transgenic ES cell clone as reference,
Cor.AtH cardiomyocytes are an ideal model for cardiac-specific
differentiation and maturation research.
In the present study, Affymetrix miRNA gene arrays and Febit
Geniom Biochips miRNA arrays have been used in parallel to
profile miRNAs during the differentiation of mouse ES cells to
cardiomyocytes. The comparison of undifferentiated ES cells with
highly pure cardiomyocytes derived from the same stem cell clone
enables the examination of changes in miRNA expression during
differentiation and maturation under defined conditions. On one
hand, the data can help in understanding the impact of platforms
in miRNA profiling and, on the other hand, assist in the
verification of miRNA profiling data obtained with the platforms.
Results
In vitro differentiation and maturation of ES cells to
cardiomyocytes
The use of pure ES cell lineages is a prerequisite to be able to
make reliable statements about changes in miRNA expression
during differentiation and maturation to cardiomyocytes. A
transgenic mouse ES cells clone (aPIG44) has been used which
harbors a genetic construct with a puromycin resistance cassette
and an EGFP reporter under the control of the cardiac a-MHC
promoter. These ES cells can be propagated continuously on
feeder cells in an undifferentiated state (Figure 1a), avoiding the
variability often observed by using different lots of primary cells.
This pure population of undifferentiated ES cells can be compared
to Cor.AtH cardiomyocytes originating from the same clone by
inducing differentiation via the formation of embryoid bodies
(Figure 1b). An essential advantage in obtaining reliable results is
that following the differentiation protocol, cells that have not
differentiated to cardiomyocytes can be killed with the selection
agent puromycin. This prevents contaminations with RNAs from
other cell types. Differentiation to Cor.AtH cardiomyocytes can be
easily monitored by the presence of the EGFP reporter gene that is
selectively expressed by cardiomyocytes. Three days after
puromycin-mediated selection for Cor.AtH cardiomyocytes, the
cells in the cardiobodies demonstrate EGFP reporter activity
(Figure 1c) which can also be seen after plating as a single cell
suspension (Figure 1d). During further culture, the cells become
larger and cell-cell contacts are established (Figure 1e, g). Striated
a-actinin structures are formed by day 19 and gap-junctions
between the cells become visible (connexin-43 staining) (Figure 1i).
The detection of which is increased by day 26 (Figure 1f, h, j).
Cor.AtH cardiomyocytes display a normal, stage-specific electro-
physiological phenotype that matches their in vivo counterparts, as
described in the literature [21,23,24] (data not shown).
The expression levels of miRNAs are distributed
differently on the two platforms
The profiling of miRNAs during differentiation and maturation
can provide a good approach to understand the process of
cardiomyocyte differentiation. For this purpose, miRNA samples
were analyzed from undifferentiated ES cells (day 0) and from cells
at different time points after differentiation to Cor.AtH cardiomy-
ocytes (i.e. days 12, 19, and 26). To authenticate the information
for miRNA changes, 2 different array platforms were chosen for
the analyses. To exclude normalization method dependent effects,
raw data of both data sets was analyzed using robust multi-array
analysis (RMA) as well as with variance stabilization normalization
(VSN). Since the miRNA platforms used were different in the
context of the oligos on the array as well as the method used for
probe-labeling, it could be assumed that the data obtained
independently from each of the platforms and their respective
normalization methods was highly valid.
miRNA Profiling in Cardiomyocyte Differentiation
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minded for the undifferentiated ES cells (day 0) and for the different
time points after differentiation (i.e. days 12, 19, and 26). A stable
number of miRNAs was observed from the analysis using the
Affymetrix platform(Table1),whilethe numberofmiRNAsincreased
significantly from time point day 0 to day 26 using the Febit platform.
A detailed list of miRNAs detected is shown in table S1.
To get an impression of the degree of similarity between the
results obtained by the two independent miRNA array platforms
the data has been presented as box-plots (Figure 2). Using this kind
of illustration, the degree of dispersion (spread) and skewness of the
data (and outliers) has been compared. In the upper part, the raw
data from Affymetrix and Febit have been plotted. The median of
the samples varied slightly as well as the distances between 25
th
and 75
th percentile values. The variances were greater in the Febit
data. However, no outlier could be identified between the samples.
The data after VSN normalization is depicted in the lower part of
figure 2. The boxes containing the 25
th to 75
th percentile have
been extended, and the variance of medians reduced. Data
generated from the Affymetrix platform demonstrated a more
even distribution than that from the Febit platform.
Samples are well clustered according to differentiation
and maturation stages
To abstract the relationship of the data, principle component
analyses (PCA) were made for data from both platforms after
RMA or VSN normalization. The first 2 components have been
plotted in figure 3. The upper part of figure 3 illustrates the PCA
plot of data after VSN normalization. The lower part shows PCA
plot data after RMA normalization. Data points from duplicate
samples were located together in both plots (circles around
duplicates), indicating that both biological replica scarcely showed
any difference in their variations. Data points were most clearly
separated in the first component axis by platform origin,
independent of the normalization method used (Figure 3). This
indicated that the results showed platform-dependent differences.
In the second component axis, data were separated according to
differentiation and maturation stages. Day 0 (undifferentiated ES
cells) samples were, as expected, far apart from the Cor.AtH
cardiomyocytes samples (days 12, 19, and 26). The distance from
day 0 to other time points was greater for Affymetrix data than for
Febit data, suggesting that Affymetrix platform was more sensitive
in miRNA profiling. Day 19 and day 26 data were not very well
separated. This phenomenon was more obvious on the Febit
platform, suggesting that day 19 and day 26 samples were similar
in miRNA expression profile.
miRNAs are differentially expressed during cardiac
differentiation
To discover the role of miRNA in cardiac differentiation and
maturation, linear models were fitted for miRNA expression data with
LIMMA package from Bioconductor. Three comparisons were made
to analyze miRNA regulation during cardiomyocyte-specific differ-
entiation and maturation: day 12 vs. day 0, day 19 vs. day 0 and day
26 vs. day 0. The results showed effects of platforms as well as of
processing methods. Histograms of expression differences and p-
values in the 3 comparisons are shown in figure 4. Results from the
Affymetrix platform showed a higher number of miRNAs with little
regulation compared to results obtained with the Febit platform.
There were also more miRNAs with low p-values after statistical
analyses for data from the Affymetrix platform.
The miRNAs that were differentially expressed in a significant
manner have been illustrated in Venn diagrams. The results from
day 12 versus day 0, day 19 versus day 0 and day 26 versus day 0,
respectively, are represented in independent Venn diagrams
(Figure 5). The 4 circles in each Venn diagram represent
significantly regulated miRNAs detected under 4 combinations
of platform and normalization methods: Affymetrix with RMA
(blue), Affymetrix with VSN (red), Febit with RMA (brown), and
Febit with VSN (green). There was a good miRNA overlap
between the 2 platforms as well as between the 2 normalization
methods. In the comparison day 12 to day 0, 31 miRNAs were
identified as regulated under all four circumstances mentioned
above. 27 miRNAs and 39 miRNAs were detected for the same
principle in comparisons of day 19 to day 0 and day 26 to day 0.
The Affymetrix platform detected far more miRNAs than the
Febit platform. For example, in the comparison of day 12 to day 0,
beside the 31 platform and pre-processing method independently
regulated miRNAs, there were 77 pre-processing method
independent regulated miRNAs detected only from the Affymetrix
platform. This number was 12 for the Febit platform. In the other
comparisons (day 19 to day 0 and day 26 to day 0) similar results
are shown (99 vs. 6 and 90 vs. 1, respectively).
To elucidate the overlapping results as well as the platform-
dependent discrepancies, 6 selected miRNAs were analyzed by
RT-qPCR assays as a third independent method. Two miRNAs
(miR-1 and miR-292-3p) represented overlapping results from
Affymetrix and Febit miRNA platforms. miR-295* represented
those miRNAs only being identified as being regulated by the
Affymetrix platform. miR-208a was an example for miRNAs
which were detected as being regulated only by the Febit platform.
miR-501-3p was selected on behalf of the group of miRNAs which
gave controversial results with the two platforms, while miR-715
represented those miRNAs not detected as being regulated by
either platform.
Figure 1. Differentiation and maturation of undifferentiated ES cells to Cor.AtH cardiomyocytes. a) Undifferentiated mouse ES cells
(clone aPIG44) on feeder cells. b) Mouse ES cells aggregated into EBs at day 3 after initiation of differentiation. c) Mouse ES cell derived Cor.AtH
cardiomyocytes after 12 days of differentiation and 3 days of puromycin treatment, before dissociation. d) Mouse ES cell derived Cor.AtH
cardiomyocytes after 12 days of differentiation and 3 days of puromycin treatment, after dissociation (probe Cor.AtH cardiomyocytes 12 days). e,g,i)
Cor.AtH cardiomyocytes after additional 7 days of culture (probe Cor.AtH cardiomyocytes 19 days): e) transmission, g) same region EGFP fluorescense
indicating differentiation to cardiomyocytes, i) overlay of immunostainings: blue=nucleus staining with DAPI, green=a-actinin (structured) and GFP,
red=connexin 43. f, h, j) Cor.AtH cardiomyocytes after additional 7 days of culture (probe CorAt 26 days): e) transmission, g) same region GFP
fluorescense indicating differentiation to cardiomyocytes, i) overlay of immunostainings: blue=nucleus staining with DAPI, green=a-actinin
(structured) and GFP, red=connexin 43.
doi:10.1371/journal.pone.0025809.g001
Table 1. Number of present miRNAs at different stages (day
0, day 12, day 19 and day 26) during cardiomyocyte specific
differentiation and maturation.
day 0 day 12 day 10 day 26
Affymetrix 318 366 323 346
Febit 71 184 211 343
doi:10.1371/journal.pone.0025809.t001
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figure 6, and have been overlaid with their intensity values on the
Affymetrix and Febit platforms. For miR-1 and miR-292-3P,
results were consistent for both miRNA array platforms and the
RT-qPCR data verified these results. This was also true for miR-
715, which showed no change in expression with all three
methods, although the absolute intensity from Affymetrix data
matched better with the Cq value of RT-qPCR. For the miRNAs
with controversial results from Affymetrix and Febit platforms, the
RT-qPCR shared results partially with Affymetrix and partially
with Febit. For example, RT-qPCR results were closer to
Affymetrix results for miR-501-3p, which showed a clear up-
regulation at day 12. This was also the case for miR-295*, for
which both Affymetrix and RT-qPCR detected a down-regulation
during the differentiation process. However, for miR-208a the
RT-qPCR result was closer to the Febit result, which detected an
up-regulation (whereas Affymetrix did not).
We selected the miRNAs, which were identified as being
regulated under all four circumstances as platform- and analysis-
independent results. All miRNAs that were identified in the
comparisons between undifferentiated ES cells and Cor.AtH
cardiomyocytes at maturation timepoints (days 12, 19, and 26)
resulted in a pool of 50 miRNAs. In the subsequent study, we
focused on these 50 miRNAs.
A closer inspection of the 50 miRNAs that were regulated in a
platform- and normalization-independent manner revealed that 18 of
these miRNAs were regulated throughout the total differentiation
and maturation process. Among these18 miRNAs, 13 were identified
as being up regulated while 5 were down regulated. There were 7
miRNAs (4 up regulated, 1 down regulated, and 2 with an unclear
trend between Affymetrix and Febit data) that were regulated
uniquely by day 12. One was down regulated only by day 19, and 13
were up regulated by day 26. Most of the 50 (31) miRNAs were
already regulated by day 12 (see Venn diagram Figure 7).
Clustering of miRNAs, which reacted similarly during cardio-
myocyte differentiation, will help in the elucidation of the miRNA
regulation pathway for cardiomyocyte differentiation. For this
purpose, heat-maps were made for the expression values of the
above-mentioned 50 miRNAs for data from both platforms
(Figure 8). Columns in the upper part of figure 8 (for Affymetrix
platform) showed that replicate samples were clustered together.
Undifferentiated samples (day 0) were separated from differenti-
ated samples (day 12, day 19 and day 26). Among differentiated
samples, day 19 was closer to day 26 than to day 12. The sample
cluster of Febit data (Figure 8 lower part) showed that replicates
from day 19 and day 26 were mixed but day 0 samples and day 12
samples were well separated. The miRNAs were clustered into 2
groups in both heat-maps. The upper group was up regulated
during the differentiation process while the lower group was down
regulated in the differentiated samples.
The selected 50 regulated miRNAs belong to cardiac
differentiation and embryonic development-related
groups
The time course of the miRNAs can tell us more about when
and how the miRNAs were regulated during cardiac differenti-
ation and maturation. For this reason the changes of expression
values of miRNAs compared to undifferentiated samples have
Figure 2. Boxplots of raw and pre-processed miRNA microarray data. Upper part left: boxplot of the raw log2 intensities of Febit miRNA
arrays, upper part right: boxplot of the raw log2 intensities of Affymetrix miRNA arrays, lower part left: VSN normalized Febit miRNA array data, and
lower part right: VSN normalized Affymetrix miRNA array data. X-axis shows sample names, Y-axis is in log2 arbitrary units. The black bar represents
the median of each distribution. The open circles represent the outliers.
doi:10.1371/journal.pone.0025809.g002
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Cluster A and cluster B were sub-groups of the up-regulated
groups in the heat-map. Cluster A included miRNAs which
increased until day 12, and then were maintained until day 26.
Typical cardio-specific miRNAs (such as miR-143) could be found
in this cluster, as well as some embryo-related miRNAs (such as
miR-298) [25]. Some of the miRNAs in this cluster were reported
to be involved in both cardiac- and embryonic-process. Cluster B
included miRNAs which continually increased during the
differentiation and maturation process. Most of the miRNAs in
cluster B were cardiac differentiation related miRNAs, though
there were also miRNAs reported as for both functions (e.g. miR-
21). miRNAs in cluster C were down regulated after the beginning
of differentiation. Many embryo miRNAs, such as miR-293, miR-
290-3p or miR-290-5p were in cluster C. Cluster C also included
miR-106a which is believed to be both ES cell-specific and
cardiac-related [26].
Target genes of differentiated expressed miRNAs are
heart development-related
miRNAs have been reported to be involved in the regulation
process through interaction with mRNA. Target prediction makes
it possible to speculate the regulation pathway of miRNA. In
mouse gene ontology, 243 genes have been annotated under the
term ‘‘GO:0007507: heart development’’. 188 miRNAs have been
predicted to be regulators for these genes. Among these 188
miRNAs, 23 were found in the 50 selected miRNAs. Six embryo
marker genes (Myc, Sox2, Klf4, Lin28, Nanog, Pou5f1) were also
predicted as regulators of miRNAs, 18 miRNAs were predicted to
be target miRNAs (data not shown). As shown by RT-qPCR, the
expression of the embryonic markers Klf4, Pou5F (Oct4) and Sox2
was completely down regulated by day 12 and remained depressed
until day 26 (Figure 10). This effect was well synchronized with the
up-regulation of miR-145.
Discussion
miRNA in murine ES cells undergoing a cardiomyocyte-specific
differentiation and maturation was profiled with the Affymetrix
GeneChip platform and the Febit Geniom Realtime Analyzer.
Instead of verifying miRNA profile results with RT-qPCR, the two
independent high throughput platforms were used to verify results
against each other. After differentiation analysis, miRNAs that
were regulated in a platform-independent manner were identified
for further study of their roles in cardiac differentiation and
maturation.
Expression level of miRNAs were distributed differently
on the two platforms
Previous studies have shown that not all miRNAs are expressed
in ES cells [15,27]. Boxplot of the data from this study also showed
that most of the miRNAs had low expression levels during the
whole cardiomyocyte-specific differentiation and maturation
process. There were more miRNAs detected in the differentiated
samples than in the undifferentiated samples, based on the Febit
platform results. However, this trend was not obvious for data
from the Affymetrix platform. Since identical samples were
applied in both studies, this could only be due to the different
design principles and detection methods used by the platforms.
Platforms and analysis methods have a strong influence
on miRNA profiling results
In the PCAplots ofthefirst2 components, anabsolute separation
was observed in the axis of the first component, suggesting that the
platforms exert a great influence on the profiling results. The
Affymetrix data points were on the negative side while the Febit
data points located on the positive side of the first principal
component. This result indicates that the choice of platform may
exert an even greater influence than the differentiation treatment
itself. Along the axis of the second principal component sub-clusters
were seen for sample from different stages during the maturation
process especially for data generated using the Affymetrix platform.
Day 0, which represents undifferentiated ES cells, is on one end of
the axis, whileday 12, day19 and day26 areon the other end of the
axis.Thisclustereffectisalsosignificantfordatageneratedusingthe
Febit platform, but day 0 was separated from other samples by less
distance. The data for the day 19 and day 26 samples were difficult
to separate on the Febit platform. This suggests that the Affymetrix
platform may possess a higher sensitivity in detecting regulation of
miRNA expression, an interpretationthat was also supportedby the
differentiation analysis. Furthermore, according to the results of the
Figure 3. Principle component analysis (PCA) plots of micro-
array data. Upper part: VSN normalized microarray data from
Affymetrix platform (black) and Febit platform (grey). Lower part:
RMA normalized data from Affymetrix platform (black) and Febit
platform (grey). Circles indicate day 0, triangles day 12, rhombuses day
19, and squares day 26. Closed symbols and open symbols represent
two replicate samples from the corresponding time points after
differentiation.
doi:10.1371/journal.pone.0025809.g003
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platform seemed to have a slight advantage over Febit miRNA
array platform. Although a larger sample size would be required to
allow a surer general statement regarding the reliability of the
miRNA array platforms, it may be concluded that the results
obtained by a single method should be considered with caution.
Analysis methods also have an influence on identifying
differentially expressed miRNAs. In our study, the same samples
analyzed on the same platform but only pre-processed with either
RMA or VSN resulted in an approximately 30% variant hit list.
For example, from the comparison of the results obtained with the
Affymetrix platform from day 12 to day 0, we identified 124
miRNAs, which were significantly regulated after applying RMA
and VSN methods. Of these miRNAs, 43 could only be identified
after VSN while 48 miRNAs could be identified only after
applying RMA. This result emphasized the importance of the
verification procedure in miRNA profiling studies, especially when
using microarray technology.
miRNAs are differentially expressed during
cardiac-specific differentiation and maturation
Despite the strong effect of platforms and pre-processing
methods, there was a clear correlation between miRNA
expression and cardiac-specific differentiation in the PCA plots.
Furthermore, miRNA expression analysis also verified the
separation of samples from undifferentiated ES cells and samples
from Cor.AtH cardiomyocytes. Fifty miRNAs were identified as
being significantly regulated in a platform- and pre-processing
independent manner. Compared to single high throughput
platform analyses, the number of regulated miRNAs that were
detected in the present study is relatively low. However, we
believe that the application of 2 independent platforms for
miRNA profiling results more plausible candidate groups. The
small number of regulated miRNAs found in the present
investigation could also be due to the use of pure populations
of Cor.AtH cardiomyocytes.
Thirty one of the 50 miRNAs had also been identified as
regulated by day 12. This result indicates that the onset of the
miRNAs changes during differentiation started before day 12.
Among these 31 miRNAs, 18 were regulated throughout the
whole differentiation and maturation period. An example of these
18 miRNAs is miR-22, which was recognized as one of the
miRNAs, which increase dramatically during differentiation.
Together with miR-21, miR-22 could regulate targets such as
transforming growth factor-b-induced gene (TGFBi) [27,28]. This
indicates the possibility of negative regulation during differentia-
tion. miR-291a-3p, miR-291a-5p, miR-292-3p, miR-290-5p and
miR-293 belong to the miR-290-295 cluster [27]. This cluster of
Figure 4. Comparison of microarray data dependent on platform used. Histograms of the log2 fold changes and adjusted p-values of
comparisons between differentiated Cor.AtH cardiomyocytes and undifferentiated ES cells for microarray data from Affymetrix (upper part) and Febit
(lower part). The comparisons are day 12 vs. day 0, day 19 vs. day 0 and day 26 vs. day 0 (from left to right).
doi:10.1371/journal.pone.0025809.g004
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the hypothesis that ES-specific miRNAs were repressed during
differentiation.
miR-21 has been intensively studied over recent years, in
particular for its involvement in cardiovascular disease and cancer
[29]. A study in 2007 [30] showed that miR-21 is up regulated in
proliferating vascular smooth muscle cells (VSMCs) of the rat.
This increase results in decreased cell proliferation and increased
cell apoptosis in a dose-dependent manner in cultured rat aortic
VSMCs. Another study found that miR-21 is strongly increased in
failing heart [31], suggesting miR-21 to be an interesting target
miRNA. Another example of up regulated miRNA is miR-145
which is significantly increased by day 12 and remains a high
expression level until day 26. OCT4, SOX2 and KLF4 can be
directly regulated by miR-145 [32]. As already known, OCT4,
SOX2 and KLF4 are required for ES cell self-renewal and
pluripotency. A high concentration of miR-145 is essential for
stem cell differentiation. As expected, the RT-qPCR results
confirmed that miR-145 target genes (Pou5F, Sox2 and Klf4)
were down regulated by day 12 and remained at a low expression
level during further cardiomyocyte maturation.
Two widely conserved miRNAs that display cardiac- and
skeletal muscle–specific expression during development and in the
adult are miR-1 and miR-133 [33], which are derived from a
common precursor transcript (bicistronic) [34,35]. miR-1 and
miR-133a were up regulated in all three comparisons (days 12, 19,
and 26) between Cor.AtH cardiomyocytes and undifferentiated ES
cells (day 0). In contrast, miR-206, which shares extensive
sequence homology to miR-1, is found expressed exclusively in
skeletal muscle with the co-transcribed miR-133b. Unsurprisingly,
an increase of miR-206 was not observed during the present
cardiomyocyte-specific differentiation process.
miR-1 has been reported to be abundant in rat heart but not in
rat artery [36]. The expression of miR-1 was reported to be
especially high in cardiac precursor cells [33,35]. Experiments also
revealed that excess miR-1 in the developing heart leads to a
decreased pool of proliferating ventricular cardiomyocytes [35].
Many results suggest that miR-1 genes modulate the effects of
critical cardiac regulatory proteins to control the balance between
differentiation and proliferation during cardiogenesis. miR-1 could
also be an important target for use in therapy of cardiovascular
disease. miR-138, which has been reported to regulate cardiac
patterning [28], was only observed to be up regulated in the
Affymetrix data but not in the Febit data.
In the time course study of the 50 selected miRNAs, miR-145
showed the highest increase by day 12, and remained at a high
expression level thereafter. This suggests that miR-145 (and the
other miRNA members of cluster A, Figure 9) is not the candidate
which triggers the maturation process of the Cor.AtH cardiomy-
ocytes during which gap-junctions are built. There are also
miRNAs such as miR-1, miR-133a and miR-133b, which
increased progressively at day 19 and day 26. Together with
miR-21, which was first regulated after the cell-cell contact (i.e.
day 12), they are good candidates to elucidate the maturation
phase of cardiac-specific differentiation.
Many recent studies have already demonstrated that miRNAs
are involved in critical biological processes. In this context,
profiling miRNA expression won increasing emphasis. miRNAs
were also believed to play an important role in ES cell
differentiation and cardiovascular diseases. In the present
manuscript paper, a transgenic mouse ES cell clone was used to
generate uniform Cor.AtH cardiomyocytes. miRNAs were profiled
for undifferentiated transgenic ES cells (day 0) and at time points
day 12, day 19 and day 26 during cardiomyocyte-specific
differentiation and maturation using 2 high throughput micro-
array platforms provided from Affymetrix and Febit. Fifty
miRNAs were identified as validly regulated from data generated
from both platforms during cardiomyocyte-specific differentiation
and maturation events. Although variation between platforms was
high, the cross-validation procedure yields more reliable data. This
provides a good basis for further research on the regulation of
pathways in cardiac differentiation and maturation. On the other
hand, our study demonstrates the necessity and efficiency of high
throughput cross platform validation to minimize invalid results
obtained by miRNA profiling with microarray platforms.
Materials and Methods
Cell culture
Mouse ES cells (D3, ATCC CRL 1934) were stably transfected
with the a-MHC–Pac–IRES–EGFP vector containing the EGFP
gene and the PuromycinR (Pac) cassette under control of the
Figure 5. Range of overlap depends on platform and pre-
processing method. Venn diagram of regulated miRNAs detected by
comparing differentiated Cor.AtH cardiomyocytes to undifferentiated ES
cells (day 0): (upper part) in comparison day 12 vs. day 0, (middle part)
in comparison day 19 vs. day 0, (lower part) in comparison day 26 vs.
day 0. Blue: Affymetrix data with RMA normalization, red: Affymetrix
data with VSN normalization, brown: Febit data with RMA normaliza-
tion, green: Febit data with VSN normalization.
doi:10.1371/journal.pone.0025809.g005
miRNA Profiling in Cardiomyocyte Differentiation
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25809cardiac a-myosin heavy chain (a-MHC) promoter as previously
described [22]. ES cells of a stably transfected clone (aPIG 44)
were cultured on mouse embroynic fibroblasts in high-glucose
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
nonessential amino acids (0.1 mM), L-glutamine (2 mM), b-
mercaptoethanol (0.1 mM), LIF (ESGR) (500 U/ml), neomycin
(6 mg/mL), and batch-tested fetal calf serum (FCS) (15% v/v) (all
Invitrogen, Karlsruhe, Germany).
To start differentiation, ES cells were trypsinized (day 0) and
cultured in suspension on a horizontal shaker (GFL 3006, GFL,
Braunschweig, Germany) to form embryoid bodies (EBs). Briefly,
ES cells were transferred into Iscove’s modified Dulbecco’s
Medium (IMDM) with 20% batch-tested FCS, nonessential
amino acids (0.1 mM) and b-mercaptoethanol (0.1 mM) (Invitro-
gen, Karlsruhe, Germany) in a 10 cm bacterial Petri dish and
cultured at 90 rpm, 37uC, 5% CO2, and 95% humidity for 48 h.
At day 2, resulting EBs were transferred into 1000 mL spinner
flasks (Integra Cell Spin, IBS, Fernwald, Germany) and cultured
for additional 7 days at 37uC, 5% CO2, and 95% humidity.
Medium was exchanged at day 5, day 7, and day 9; and
Puromyicn (5 mg/mL) was added to select for cardiomyocytes at
day 9. At day 12, remaining cardiobodies (embryoid bodies
consisting of cardiomyocytes, Figure 1c) were trypsinized to
obtain a single cell suspension of cardiomyocytes (Cor.AtH
cardiomyocytes) (Figure 1d).
Figure 6. Evaluation of Array results for 6 selected miRNAs by RT-qPCR miRNA assays. RT-qPCR of selected miRNAs at day 0, day 12, day
19 and day 26 in comparison to Affymetrix and Febit array results are shown. Upper part: The log2 intensities of the samples analyzed by arrays (left
scale) and the quantitative cycles Cq detected by RT-qPCR miRNA assays (right scale) are illustrated. Lower part: Log2 fold change of the amount of
miRNA at the day indicated in comparison to day 0. Solid lines represent results from RT-qPCR miRNA assays; dashed lines represent results for
Affymetrix array measurements; dotted lines represent results for Febit array measurements; dashed-dotted lines represent the Cq values of the RT-
qPCR reference small nucleolar RNA snoRNA 202.
doi:10.1371/journal.pone.0025809.g006
Figure 7. Venn diagram of the 50 platform and pre-processing
methods independent regulated miRNAs. The number of up/
down regulated miRNAs at different maturation stages (day 12, day 19
and day 26) compared to undifferentiated ES cells were denoted with
arrows up/down.
doi:10.1371/journal.pone.0025809.g007
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6 Cor.AtH cardiomyocytes each were then seeded onto
Fibronectin-coated 10 cm dishes (Becton Dickinson, Heidelberg,
Germany) in IMDM medium as described above and cultured at
37uC, 5% CO2, and 95% humidity with daily media changes. All
micorphotographs were taken using an Axiovert 100 M (Zeiss,
Jena, Germany) equipped with a FITC filter set (AF Analysen-
technik, Stuttgart, Germany).
Immunostaining
For immunostaining, Cor.AtH cardiomyocytes were seeded at
2610
5 cells/well on fibronectin-coated 24 well plates in IMDM
20% FCS and cultured as described above. At day 7 and day 14
after seeding (day 19 and day 26 after differentiation), cells were
washed twice with PBS, fixed with 4% PFA for 30 minutes,
permeabilized with 0.1% (w/v) Saponin in PBS for 30 minutes,
and blocked for 1 h with 5% (w/v) BSA in PBS (all at RT).
Between each of the following steps, cells were washed 36using
PBS with 0.8% (w/v) BSA and 0.1% (w/v) Saponin (PBS*).
Immunostaining for a-Actinin was performed by incubating the
cells with a monoclonal anti-a-Actinin antibody (Sigma-Aldrich,
Munich, Germany) diluted 1:100 in PBS* at 4uC overnight,
followed by incubation with a Cy2 conjugated goat-anti-mouse
IgG anitbody (Sigma-Aldrich, Munich, Germany) diluted 1:200 in
PBS* for 1 h at 37uC.
Afterwards, the immunostaining for Connexin 43 was per-
formed by incubating the pre-stained cells with a rabbit-anti-
mouse Cx43 IgG antibody (Biotrend, Cologne, Germany) diluted
1:200 in PBS* at 4uC overnight, followed by an incubation with a
Cy3 conjugated goat-anti-rabbit IgG antibody (Dianova, Ham-
burg, Germany) diluted 1:200 in PBS* for 1 h at 37uC. Cells were
washed, and nuclei were stained with DAPI (1 mg/mL, Sigma-
Aldrich, Munich, Germany) diluted in PBS* for 5 minutes at RT.
After a final washing step, cells were covered with PBS and
analyzed using an Axiovert 100 M (Zeiss, Jena, Germany)
equipped with a Cy3 and a Cy2 filter set (AF Analysentechnik,
Stuttgart, Germany).
RNA isolation, quantification, and quality control
For day 0 RNA, ES cells were trypsinized at day -2, seeded onto
a gelatin-coated 6 cm TC dish (Becton Dickinson, Heidelberg,
Germany), and cultured for 48 h in DMEM 15% FCS as
described above. The timing of this last passage was in parallel
with the ES cell passage used to initiate differentiation.
For day 12 RNA, Cor.AtH cells were seeded onto a Fibronectin
coated 10 cm dish as described above and cultured for 6 h. The
Cor.AtH cardiomyocytes attached to the surface of the dish;
remaining dead cells from the selection procedure were washed off
before isolating day 12 RNA.
For all other days, RNA was prepared from the 10 cm dishes
after washing the plates 26with PBS. Total RNAs from cells after
timepoints indicated were extracted by using PeqGold RNApure
(Peqlab Biotechnology, Erlangen, Germany) according to the
manufacturer’s instructions. Quantity of total RNA was measured
using a NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). Optical density values at
260/280 were consistently above 1.9. The total RNA Quality was
assayed on an Agilent BioAnalyzer (Agilent Technologies, Santa
Clara, CA, USA). Only samples with intact, distinct ribosomal
peaks were chosen for further analysis.
RT-qPCR
Gene expression assays. First strand cDNA was reverse
transcribed from 500 ng of total RNA using Superscript
TMII Reverse
Transcriptase, Oligo (dT)12–18 and random hexamer primers
according to the manufacturer’s instructions (Invitrogen, Karlsruhe,
Germany). Glycerinaldehyde-3-phosphate dehydrogenase (GAPDH),
Kru ¨ppel like factor 4 (Klf4), Pou domain class 5 (Pou5f1/Oct4), and
SRY-containg gene 2 (Sox2) were quantified using Individual
TaqManH Gene Expression Assays (Applied Biosystems, Foster
City, CA, USA) on an ABI 7300 Real-Time PCR System. cDNA
(25 ng) was mixed with TaqManH Gene Expression Master Mix
(Applied Biosystems, Foster City, CA, USA) and the appropriate
TaqManH Gene Expression Assays (Applied Biosystems, Foster City,
CA, USA) for the gene of interest: (GAPDH - 4352932E, Klf4 -
Mm00516104_m1, Pou5f1/Oct4 - Mm0353917_g1, Sox2 -
Mm03053810_s1). To calculate relative gene expression we used
the comparative quantification cycle (Cq)m e t h o d( 2
2DDCq) [37]. All
reactions were performed in triplicate and relative gene expression was
normalized to the reference gene GAPDH. The results are expressed
as fold change over day 0 values.
Micro RNA assays. Validation of expression of selected
miRNAs was performed using commercially available pre-
designed TaqMan RT-qPCR assays (Applied Biosystems, Foster
City, CA, USA) using the same RNA samples as used for the
microarray profiling. The TaqManH MicroRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA)
was used for the preparation of cDNA. Reverse transcription
reactions were performed in a volume of 20 mLa t1 6 uC for
30 minutes, at 42uC for 30 minutes, and then terminated at 85uC
for 5 minutes. Each reaction contained 20 ng of total RNA, and
multiple (heptaplex) stem-loop miRNA-specific primers from the
TaqMan MicroRNA Assays (each 12.5 nM), 2 mM dNTPs,
100 U MultiScribe
TM Reverse Transcriptase, 16Reverse Transcrip-
tion buffer, and 5 U RNase Inhibitor. For qPCR of individual
TaqMan MicroRNA Assays we used 0.75 mLTaqMan MicroRNA
Assay Primer, 1.2 mL cDNA (10-fold diluted), 7.5 mLT a q M a n2 6
universal PCR master mix without UNG, and 5.55 mLn u c l e a s e - f r e e
water. All TaqMan MicroRNA Assays were run on an Applied
Biosystems 7300 Real-Time PCR System with the following
conditions: an initial step of 10 minutes at 95uC, followed by 40
cycles of 15 s at 95uCa n d1m i n u t ea t6 0 uC. The assays used were:
hsa-miR-208, hsa-miR-1, mmu-miR-292-3p, mmu-miR-295#,
mmu-miR-501#, mmu-miR-715, and the small nucleolar RNA
snoRNA202 as reference. To calculate relative miRNA expression
we used the comparative quantification cycle (Cq) method (2
2DDCq)
[37]. All reactions were performed in triplicate, and relative miRNA
expression was normalized to expression of the reference small
nucleolar RNA snoRNA202. Results are expressed as fold change
over day 0 values. To illustrate the abundance of the miRNAs the Cq
values before normalization are also presented.
Affymetrix miRNA labelling, array hybridization and data
pre-processing
Total RNA containing low molecular weight RNA was labelled
using the Flashtag RNA labeling kit (Genisphere, Hatfield, PA,
USA) according to the manufacturer’s instructions. Briefly, for
each sample, 2 mg total RNA were subjected a tailing reaction
(2.5 mM MnCl2, ATP, Poly A Polymerase - incubation for
15 minutes at 37u) followed by ligation of the biotinylated signal
Figure 8. Heatmap of expression values of the 50 platform and pre-processing methods independent regulated miRNAs from
Affymetrix platform (upper part) and Febit platform (lower part).
doi:10.1371/journal.pone.0025809.g008
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biotin, T4 DNA ligase - incubation for 30 minutes at RT) and
adding of stop solution.
Each sample was hybridized to a GeneChipH miRNA Array
(Affymetrix, Santa Clara, CA, USA) at 48uC and 60 rpm for
16 hours then washed and stained on Fluidics Station 450 (Fluidics
script FS450_0003) and finally scanned on a GeneChipH Scanner
3000 7G (Affymetrix). The image data were analyzed with the
miRNA QC Tool software for quality control (www.affymetrix.
com/products_services/arrays/specific/mi_rna.affx#1_4). For
each time point two independent experiments were performed
under identical conditions. The expression values were summa-
rized and normalized respectively with robust multi-array average
(RMA) [38] and variance stabilization method (VSN) [39] using
RMA and VSN packages in Bioconductor 2.5 under R 2.10 [40].
Febit miRNA labelling, array hybridization and data
pre-processing
The same samples were analyzed with a Geniom Realtime
Analyzer (GRTA, Febit GmbH, Heidelberg, Germany) using the
Geniom Biochip miRNA mus musculus. Each array contains 8
replicates of 710 miRNAs and miRNA star sequences as annotated
in the Sanger miRBase 14.0. Sample labelling with biotin was
carried out by microfluidic-based enzymatic on-chip labelling of
miRNAs (MPEA) as described before [41]. Following hybridization
for 16 hours at 42uC the biochip was washed automatically and a
program for signal enhancement was processed with the GRTA.
The resulting detection pictures were evaluated using the Geniom
Wizard Software. For each array, the median signal intensity was
extracted from the raw data file such that for each miRNA eight
intensity values were calculated corresponding to each replicate
copy of miRBase on the array. Following background correction,
the eight replicate intensity values of each miRNA were
summarized by their median value. To normalize the data across
different arrays, quantile normalization and VSN were applied and
all further analyses were carried out using the normalized and
background subtracted intensity values.
Bioinformatic analyses of Affymetrix and Febit miRNA
microarray data
The overlapped miRNAs on both platforms were selected
according to annotations provided from the corresponding chip
manufacturer. The expression values of these overlapped miRNAs
were then used for further analysis. Present/absent calls were made
for both platforms. For Affymetrix detection, p-values were decided
by Wilcoxon-test and Affymetrix-test; probe-sets with a p-value
lower than 0.06 were called present. For Febit platform, a boolean
value p is computed for every probe. This value indicates whether
the respective miRNA is present or not. For a probe with intensity






. Where Bn denotes the mean intensity
of blank controls and sdn indicates standard deviation of blank
controls. Assuming that blank controls are normally distributed, the
significance value for each probe would be 0.001.
Principle component analysis (PCA) was applied on normalized
data from each of the platforms. The first 2 components of PCA
were plotted using R [42]. Boxplots of the raw log2 intensities of
both platforms as well as VSN normalized data were made using
R function. Linear models were fitted for both datasets in order to
distinguish differentially expressed miRNAs between different time
points on the Affymetrix platform and the Febit platform,
respectively (Linear Models for Microarray Data (LIMMA)
Bioconductor package [43]). Comparisons were made between
undifferentiated samples (day 0) and each of the differentiated
samples (days 12, 19 and 26). The miRNAs, which showed
adjusted p-value lower than 0.05, were selected as significantly
differentially expressed. Venn diagrams and histograms for
differential expression analysis results were made using R
functions. Additionally, cluster analysis was made for the platform
independent regulated miRNAs by using R functions. Target
prediction of miRNAs was done using MIRror [44].
All array data are MIAME compliant. The raw data has been
deposited in Gene Expression Omnibus (GEO) - Accession
number: GSE24066.
Supporting Information
Table S1 Complete list of all mouse miRNAs on both platforms;
the miRNAswerecategorized according to theirpresent/absentcall.
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Figure 9. Changes in expression of selected miRNAs during time course of cardiomyocyte-specific differentiation/maturation. Three
expression clusters of the 50 platform and pre-processing methods independent regulated miRNAs. (Cluster A) miRNAs which increased at day 12
and keep highly expressed afterwards, (Cluster B) miRNAs which incease continuously, (Cluster C) miRNAs which are down regulated during
differentiation. miRNA names are colored in red for according to literature cardiac-related miRNAs and blue for according to literature ES cell related
miRNAs. Y-axis represents log2 fold change over undifferentiated ES cells (day 0). miRNAs showing discrepancies in cluster membership dependent
on array platform are marked with (a) for the Affymetrix and (f) for the febit result.
doi:10.1371/journal.pone.0025809.g009
Figure 10. Embryonic marker genes are down regulated at day
12 of cardiomyocyte-specific differentiation. mRNA levels were
measured at indicated timepoints using RT-qPCR. Relative gene
expression of ES cell markers Klf4, Pou5F and Sox2 normalized to the
expression of the reference gene GAPDH is shown. The results are
expressed as fold change over day 0 values (undifferentiated ES cells).
The y-axis represents log2 fold change relative to day 0.
doi:10.1371/journal.pone.0025809.g010
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